TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (Q3)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q9)Dec 31, 2022 | (Q6)Sep 30, 2022 | (Q3)Jun 30, 2022 | (FY)Mar 31, 2022 | (Q9)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -3.16%48.98M | 33.70%91.85M | 54.12%50.58M | 81.00%27.66M | -19.73%68.7M | -37.40%50.13M | -35.47%32.82M | -37.66%15.28M | -12.15%85.59M | 1.88%80.07M |
Operating income | -3.16%48.98M | 33.70%91.85M | 54.12%50.58M | 81.00%27.66M | -19.73%68.7M | -37.40%50.13M | -35.47%32.82M | -37.66%15.28M | -12.15%85.59M | 1.88%80.07M |
Operating expenses | ||||||||||
Gross profit | ||||||||||
Employee expense | 36.60%-11.49M | 16.85%-32.3M | -24.51%-18.12M | -39.40%-9.3M | -19.13%-38.84M | 14.65%-22.23M | 18.14%-14.55M | 24.72%-6.67M | 22.42%-32.61M | 16.05%-26.04M |
Depreciation and amortization | 14.33%-6.22M | 2.43%-12.14M | -7.56%-7.26M | -6.42%-3.69M | 17.28%-12.45M | 15.26%-10.34M | 19.87%-6.75M | 17.65%-3.47M | 39.04%-15.05M | 38.67%-12.21M |
Revaluation surplus | ---- | --13.38M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Changes in the fair value of other assets | ---- | --13.38M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provision | ---- | ---395K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairment is provision | ---- | ---395K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of operating profit | -24.33%-41.51M | 4.11%-51.46M | -18.10%-33.39M | -21.95%-17.61M | -62.99%-53.66M | -33.33%-40.73M | -98.10%-28.27M | -3,065.09%-14.44M | 0.85%-32.93M | -72.15%-30.55M |
Operating profit | -24.99%-10.23M | 124.66%8.94M | 51.14%-8.18M | 68.39%-2.94M | -823.68%-36.25M | -305.53%-23.17M | -261.23%-16.75M | -177.95%-9.3M | -54.50%5.01M | 13.62%11.28M |
Financing cost | -8.87%-626K | -34.64%-1.07M | -39.90%-575K | -38.42%-281K | 26.76%-791K | 75.58%-555K | 57.19%-411K | 39.76%-203K | 52.53%-1.08M | -34.34%-2.27M |
Earning before tax | -23.93%-10.86M | 121.26%7.87M | 48.96%-8.76M | 66.11%-3.22M | -1,042.73%-37.04M | -363.59%-23.73M | -282.00%-17.16M | -181.97%-9.5M | -55.02%3.93M | 9.37%9M |
Tax | 83.25%-34K | -84.51%374K | ---203K | ---202K | 2,553.85%2.42M | ---- | ---- | ---- | 468.75%91K | ---758K |
After-tax profit from continuing operations | -21.50%-10.89M | 123.82%8.25M | 47.78%-8.96M | 63.98%-3.42M | -961.32%-34.63M | -387.82%-23.73M | -283.54%-17.16M | -181.97%-9.5M | -54.06%4.02M | 0.16%8.24M |
Earning after tax | -21.50%-10.89M | 123.82%8.25M | 47.78%-8.96M | 63.98%-3.42M | -961.32%-34.63M | -387.82%-23.73M | -283.54%-17.16M | -181.97%-9.5M | -54.06%4.02M | 0.16%8.24M |
Minority profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -92.17%13K | -72.86%19K |
Profit attributable to shareholders | -21.50%-10.89M | 123.82%8.25M | 47.78%-8.96M | 63.98%-3.42M | -964.11%-34.63M | -388.49%-23.73M | -283.50%-17.16M | -181.94%-9.5M | -53.33%4.01M | 0.78%8.23M |
Basic earnings per share | -2.15%-0.0095 | 123.82%0.0086 | 48.04%-0.0093 | 63.64%-0.0036 | -959.52%-0.0361 | -387.21%-0.0247 | -284.54%-0.0179 | -181.82%-0.0099 | -57.58%0.0042 | -12.24%0.0086 |
Diluted earnings per share | -2.15%-0.0095 | 123.27%0.0084 | -0.0093 | -959.52%-0.0361 | 0.0042 | |||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | -- | Fan Chen Certified Public Accountants Co., Ltd. | -- | -- | Fan Chen Certified Public Accountants Co., Ltd. | -- | -- | -- | Kaiyuan Shun Tak Certified Public Accountants Limited | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.